These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
88 related items for PubMed ID: 8383359
1. A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo. Asselbergs FA, Bürgi R, Hamerman J, Heim J, van Oostrum J, Agnelli G. Thromb Haemost; 1993 Jan 11; 69(1):50-5. PubMed ID: 8383359 [Abstract] [Full Text] [Related]
2. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D. Thromb Haemost; 1991 Dec 02; 66(6):684-93. PubMed ID: 1796414 [Abstract] [Full Text] [Related]
3. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase. Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D. Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163 [Abstract] [Full Text] [Related]
4. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR. Fowler B, Mackman N, Parmer RJ, Miles LA. Thromb Haemost; 1998 Jul 03; 80(1):148-54. PubMed ID: 9684801 [Abstract] [Full Text] [Related]
5. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase. Corti A, Sarubbi E, Soffientini A, Nolli ML, Zanni A, Galimberti M, Parenti F, Cassani G. Thromb Haemost; 1989 Nov 24; 62(3):934-9. PubMed ID: 2480654 [Abstract] [Full Text] [Related]
6. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains. Emeis JJ, Verheijen JH. Arzneimittelforschung; 1992 Mar 24; 42(3):358-62. PubMed ID: 1497699 [Abstract] [Full Text] [Related]
7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J. Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138 [Abstract] [Full Text] [Related]
13. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor. Piedagnel R, Tiger Y, Lelongt B, Ronco PM. J Cell Physiol; 2006 Feb 02; 206(2):394-401. PubMed ID: 16155905 [Abstract] [Full Text] [Related]
14. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. Fibbi G, D'Alessio S, Pucci M, Cerletti M, Del Rosso M. Biol Chem; 2002 Jan 02; 383(1):127-36. PubMed ID: 11928807 [Abstract] [Full Text] [Related]
15. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Mars WM, Kim TH, Stolz DB, Liu ML, Michalopoulos GK. Cancer Res; 1996 Jun 15; 56(12):2837-43. PubMed ID: 8665523 [Abstract] [Full Text] [Related]